101 related articles for article (PubMed ID: 9925253)
1. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.
Britten RA; Perdue S; Opoku J; Craighead P
Radiother Oncol; 1998 Sep; 48(3):329-34. PubMed ID: 9925253
[TBL] [Abstract][Full Text] [Related]
2. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract][Full Text] [Related]
3. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity.
Rasouli-Nia A; Liu D; Perdue S; Britten RA
Clin Cancer Res; 1998 May; 4(5):1111-6. PubMed ID: 9607567
[TBL] [Abstract][Full Text] [Related]
4. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract][Full Text] [Related]
5. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
6. Development of an in vitro chemo-radiation response assay for cervical carcinoma.
Monk BJ; Burger RA; Parker R; Radany EH; Redpath L; Fruehauf JP
Gynecol Oncol; 2002 Nov; 87(2):193-9. PubMed ID: 12477451
[TBL] [Abstract][Full Text] [Related]
7. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells.
Hennequin C; Giocanti N; Favaudon V
Cancer Res; 1996 Apr; 56(8):1842-50. PubMed ID: 8620502
[TBL] [Abstract][Full Text] [Related]
8. Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway.
Su WH; Chuang PC; Huang EY; Yang KD
Am J Pathol; 2012 Feb; 180(2):862-71. PubMed ID: 22138581
[TBL] [Abstract][Full Text] [Related]
9. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines.
Britten RA; Evans AJ; Allalunis-Turner MJ; Pearcey RG
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):367-74. PubMed ID: 8567337
[TBL] [Abstract][Full Text] [Related]
10. [Radiosensitization by paclitaxel. The in-vivo results in paclitaxel-sensitive and -resistant tumors].
Vogt HG; Zamboglou N
Strahlenther Onkol; 1998 Oct; 174(10):539-40. PubMed ID: 9810324
[No Abstract] [Full Text] [Related]
11. Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines.
Erlich E; McCall AR; Potkul RK; Walter S; Vaughan A
Gynecol Oncol; 1996 Feb; 60(2):251-4. PubMed ID: 8631547
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
14. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Kamer S; Ren Q; Dicker AP
Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
[TBL] [Abstract][Full Text] [Related]
15. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
Tanaka T; Bai T; Yukawa K; Umesaki N
Oncol Rep; 2006 Apr; 15(4):939-47. PubMed ID: 16525683
[TBL] [Abstract][Full Text] [Related]
16. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
18. C-raf-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance.
Warenius HM; Browning PG; Britten RA; Peacock JA; Rapp UR
Eur J Cancer; 1994; 30A(3):369-75. PubMed ID: 8204361
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.
Galmarini CM; Falette N; Tabone E; Levrat C; Britten R; Voorzanger-Rousselot N; Roesch-Gateau O; Vanier-Viornery A; Puisieux A; Dumontet C
Br J Cancer; 2001 Sep; 85(6):902-8. PubMed ID: 11556844
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells.
Balcer-Kubiczek EK; Attarpour M; Jiang J; Kennedy AS; Suntharalingam M
Chemotherapy; 2006; 52(5):231-40. PubMed ID: 16899972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
